Chiang, Chern EnChern EnChiangUeng, Kwo ChangKwo ChangUengChao, Ting HsingTing HsingChaoLin, Tsung-HsienTsung-HsienLinWu, Yih JerYih JerWuWang, Kang LingKang LingWangSung, Shih HsienShih HsienSungYeh, Hung I.Hung I.YehLi, Yi HengYi HengLiLiu, Ping YenPing YenLiuChang, Kuan ChengKuan ChengChangShyu, Kou GiKou GiShyuHuang, Jin LongJin LongHuangTsai, Cheng DaoCheng DaoTsaiHung, Huei FongHuei FongHungLiu, Ming EnMing EnLiuChao, Tze FanTze FanChaoCheng, Shu MengShu MengChengCheng, Hao MinHao MinChengChu, Pao HsienPao HsienChuYin, Wei HsianWei HsianYinYEN-WEN WUWEN-JONE CHENLai, Wen TerWen TerLaiLin, Shing JongShing JongLinYeh, San JouSan JouYehJUEY-JEN HWANGHou, Charles Jia YinCharles Jia YinHou2022-08-052022-08-052021-09-0127723747https://scholars.lib.ntu.edu.tw/handle/123456789/616203Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.antidiabetic agents | chronic kidney disease | heart failure | Taiwan Society of Cardiology | type 2 diabetesreview10.1016/j.jacasi.2021.08.0032-s2.0-85132144478